Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

NCT01128426

Last updated date
Study Location
Northern California Kaiser Permanente
Oakland, California, 94612, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-3 months
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Infants starting vaccination with 13vPnC in the first 6 months of life who are members of the Northern California Kaiser Permanente healthcase system and who receive at least 1 dose of 13vPnC during the study observation period will be included. Infants must not have had 7vPnC at the time of 13vPnC dose administration.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Infants and children who were previously vaccinated with any number of doses of 7vPnC
will be excluded.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
  1. Paramount, California
  2. Colorado Springs, Colorado
  3. Apopka, Florida
  4. Gainesville, Florida
  5. Gainesville, Florida
  6. Miami, Florida
  7. Miami, Florida
  8. Nampa, Idaho
  9. El Dorado, Kansas
  10. Baton Rouge, Louisiana
  11. Covington, Louisiana
  12. Missoula, Montana
  13. Albuquerque, New Mexico
  14. Dayton, Ohio
  15. Fairfield, Ohio
  16. Erie, Pennsylvania
  17. Charleston, South Carolina
  18. Cheraw, South Carolina
  19. North Charleston, South Carolina
  20. Kaysville, Utah
  21. Layton, Utah
  22. Murray, Utah
  23. Murray, Utah
  24. Roy, Utah
  25. Saint George, Utah
  26. Syracuse, Utah
  27. Charlottesville, Virginia
  28. Charlottesville, Virginia
  29. Charlottesville, Virginia
  30. Guayama,
  31. Dothan, Alabama
  32. Fayetteville, Arkansas
  33. Ontario, California
  34. Homestead, Florida
  35. Chamblee, Georgia
  36. Idaho Falls, Idaho
  37. Idaho Falls, Idaho
  38. Bardstown, Kentucky
  39. Louisville, Kentucky
  40. Haughton, Louisiana
  41. Lincoln, Nebraska
  42. Lincoln, Nebraska
  43. Dayton, Ohio
  44. East Norriton, Pennsylvania
  45. Bristol, Tennessee
  46. Kingsport, Tennessee
  47. Houston, Texas
  48. San Antonio, Texas
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
NCT04379713
  1. Fort Myers, Florida
  2. Naples, Florida
  3. Blackfoot, Idaho
  4. Statesville, North Carolina
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal DiseaseSerotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.
NCT01564771
  1. Athens, Attiki
  2. Alexandroupoli, Evros
  3. Alexandroupoli,
  4. Athens,
  5. Athens,
  6. Athens,
  7. Athens,
  8. Athens,
  9. Athens,
  10. Athens,
  11. Athens,
  12. Athens,
  13. Athens,
  14. Athens,
  15. Athens,
  16. Athens,
  17. Athens,
  18. Athnens,
  19. Kavala,
  20. Kavala,
  21. Larissa,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pneumococcal DiseaseChild Pneumococcal Serotype Epidemiology In Greece
NCT01111214
  1. Athens, Attiki
  2. Alexandroupoli,
  3. Herakleion,
  4. Herakleion,
  5. Ioannina,
  6. Larissa,
  7. Thessaloniki,
  8. Thessaloniki,
  9. Trikala,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers
Official Title Postlicensure Observational Safety Study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Administered in Routine Use to Infants and Toddlers
Brief Summary The purpose of the study is to expand the understanding of the safety profile of 13vPnC in routine use following licensure and introduction of the vaccine.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population 60,000 infants total: at least 43,000 infants who receive all 3 primary series doses of 13vPnC plus 15,000 additional infants who receive less than 3 doses of 13vPnC
Condition Pneumococcal Disease
Intervention Other: No Intervention
No Intervention
Study Groups/Cohorts 1
Intervention: Other: No Intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: June 12, 2014)
53902
Original Estimated Enrollment
 (submitted: May 20, 2010)
60000
Actual Study Completion Date June 2013
Actual Primary Completion Date June 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Infants starting vaccination with 13vPnC in the first 6 months of life who are members of the Northern California Kaiser Permanente healthcase system and who receive at least 1 dose of 13vPnC during the study observation period will be included. Infants must not have had 7vPnC at the time of 13vPnC dose administration.

Exclusion Criteria:

  • Infants and children who were previously vaccinated with any number of doses of 7vPnC will be excluded.
Sex/Gender
Sexes Eligible for Study:All
Ages 2 Months to 3 Years   (Child)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01128426
Other Study ID Numbers 6096A1-4002
B1851044
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Kaiser Permanente
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2014